APLS

40.41

0.05% 0.02

Dopo l'orario di chiusura: 40.41

Apellis Pharmaceuticals Inc (APLS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché APLS Giù? Forum Previsione

Precedente Chiudi:

$40.39

Aprire:

$40.37

Volume 24 ore:

10.33M

Relative Volume:

2.23

Capitalizzazione di mercato:

$5.17B

Reddito:

$1.00B

Utile/perdita netta:

$22.39M

Rapporto P/E:

327.21

EPS:

0.1235

Flusso di cassa netto:

$45.01M

1 W Prestazione:

+129.08%

1M Prestazione:

+95.22%

6M Prestazione:

+74.86%

1 anno Prestazione:

+75.70%

Intervallo 1D:

$40.35

$40.48

Intervallo di 1 settimana:

$16.83

$40.48

Portata 52W:

$16.10

$40.48

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Nome

Apellis Pharmaceuticals Inc

Settore

Healthcare (1118)

Industria

Biotechnology (624)

Telefono

617-977-5700

Indirizzo

100 FIFTH AVENUE, WALTHAM, KY

Dipendente

733

Cinguettio

@ApellisPharma

Prossima data di guadagno

2024-12-05

Ultimi documenti SEC

APLS's Discussions on Twitter

Compare APLS vs VRTX, REGN, ARGX, ALNY, INSM

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
APLS Apellis Pharmaceuticals Inc	40.41	5.17B	1.00B	22.39M	45.01M	0.1235
VRTX Vertex Pharmaceuticals Inc	438.71	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	761.85	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	746.42	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	318.85	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	162.43	35.01B	606.42M	-1.28B	-997.58M	-6.403

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-13	Iniziato	Roth Capital	Buy
2026-01-28	Iniziato	Barclays	Equal Weight
2026-01-21	Aggiornamento	BofA Securities	Neutral → Buy
2025-11-06	Iniziato	Wolfe Research	Peer Perform
2025-10-15	Iniziato	Wells Fargo	Overweight
2025-09-26	Downgrade	Goldman	Neutral → Sell
2025-05-09	Downgrade	BofA Securities	Buy → Neutral
2025-05-09	Downgrade	Raymond James	Strong Buy → Outperform
2025-04-29	Iniziato	Cantor Fitzgerald	Overweight
2024-12-17	Downgrade	Goldman	Buy → Neutral
2024-11-21	Iniziato	Morgan Stanley	Equal-Weight
2024-10-25	Iniziato	RBC Capital Mkts	Sector Perform
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-10-16	Iniziato	William Blair	Outperform
2024-05-31	Iniziato	Piper Sandler	Neutral
2024-02-05	Aggiornamento	Jefferies	Hold → Buy
2023-12-14	Downgrade	Wells Fargo	Overweight → Equal Weight
2023-11-09	Iniziato	Goldman	Buy
2023-11-02	Iniziato	Mizuho	Neutral
2023-10-06	Aggiornamento	JP Morgan	Neutral → Overweight
2023-09-15	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-08-29	Reiterato	Citigroup	Buy
2023-08-03	Downgrade	JP Morgan	Overweight → Neutral
2023-08-01	Downgrade	BofA Securities	Buy → Neutral
2023-01-03	Downgrade	Wells Fargo	Overweight → Equal Weight
2022-11-10	Downgrade	Jefferies	Buy → Hold
2022-07-19	Iniziato	H.C. Wainwright	Buy
2022-06-17	Ripresa	Stifel	Buy
2022-04-14	Downgrade	ROTH Capital	Neutral → Sell
2021-12-08	Iniziato	Wells Fargo	Overweight
2021-11-29	Downgrade	ROTH Capital	Buy → Neutral
2021-09-10	Reiterato	BMO Capital Markets	Outperform
2021-09-10	Reiterato	Credit Suisse	Neutral
2021-09-10	Reiterato	Needham	Buy
2021-09-10	Reiterato	Oppenheimer	Outperform
2021-09-10	Downgrade	Wedbush	Outperform → Neutral
2021-08-19	Iniziato	Jefferies	Buy
2021-08-19	Aggiornamento	Wedbush	Neutral → Outperform
2021-05-21	Iniziato	UBS	Buy
2021-04-16	Iniziato	Goldman	Buy
2020-11-19	Iniziato	Needham	Buy
2020-09-01	Iniziato	Stifel	Buy
2020-07-20	Iniziato	ROTH Capital	Buy
2020-06-17	Iniziato	BTIG Research	Neutral
2020-04-01	Iniziato	Raymond James	Strong Buy
2020-03-31	Iniziato	BMO Capital Markets	Outperform
2020-03-11	Aggiornamento	Wedbush	Underperform → Neutral
2020-01-07	Iniziato	SVB Leerink	Mkt Perform
2019-12-19	Iniziato	BofA/Merrill	Buy
2019-11-22	Iniziato	Wedbush	Underperform
2019-11-05	Iniziato	Credit Suisse	Neutral
2019-08-01	Reiterato	Cantor Fitzgerald	Overweight
2019-07-12	Aggiornamento	JP Morgan	Neutral → Overweight
2019-03-29	Iniziato	Robert W. Baird	Outperform
2019-01-23	Downgrade	JP Morgan	Overweight → Neutral
2018-07-30	Aggiornamento	B. Riley FBR	Neutral → Buy
2018-05-24	Iniziato	Cantor Fitzgerald	Overweight
2018-04-12	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
2018-02-08	Iniziato	B. Riley FBR, Inc.	Buy

Mostra tutto

Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie

Apr 04, 2026

Biogen’s Apellis Deal Reshapes Growth Outlook And Valuation Story - Yahoo Finance

Apr 04, 2026

APLS PE Ratio & Valuation, Is APLS Overvalued - intellectia.ai

Apr 04, 2026

Biogen Bets Big on Kidney Drugs with USD 5.6 Billion Apellis Pharmaceuticals Deal - Medical Dialogues

Apr 04, 2026

Apr 03, 2026

Apellis Pharmaceuticals (APLS) hits 2-year high on 140% upside from Biogen merger - MSN

Apr 03, 2026

Biogen (NASDAQ: BIIB) plans tender offer to acquire Apellis (APLS); materials pending - Stock Titan

Apr 03, 2026

Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy - Benzinga

Apr 03, 2026

Biogen to acquire Apellis in $5.6 billion deal - Ophthalmology Times

Apr 03, 2026

Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded by Roth Mkm to "Hold" - MarketBeat

Apr 03, 2026

Comparing Apellis Pharmaceuticals With Industry Competitors In Biotechnology Industry - Sahm

Apr 03, 2026

Apellis surges on $5.6B buyout deal with Biogen - MSN

Apr 03, 2026

Apr 02, 2026

APLS Stock Soars 140% Today – Here’s Everything To Know About Apellis' Massive $5.6B Deal With Biogen - Stocktwits

Apr 02, 2026

Biogen’s $5.6 Billion Apellis Buy Drives Top Trading Volume Amid Share Price Slide - Bitget

Apr 02, 2026

Why Biogen Is Paying $5.6B to Buy Apellis Pharma - MedCity News

Apr 02, 2026

Apellis Pharmaceuticals (APLS): Mizuho Raises Price Target Amids - GuruFocus

Apr 02, 2026

Mizuho Increases Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $41.00 - MarketBeat

Apr 02, 2026

Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded to "Hold" Rating by Jefferies Financial Group - MarketBeat

Apr 02, 2026

Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded to "Hold" Rating by William Blair - MarketBeat

Apr 02, 2026

Apellis Pharmaceuticals (NASDAQ:APLS) Lowered to Hold Rating by Citigroup - MarketBeat

Apr 02, 2026

H.C. Wainwright raises Biogen stock price target on Apellis deal - Investing.com

Apr 02, 2026

Apellis Pharmaceuticals (NASDAQ:APLS) Emerges as a Prime Affordable Growth (GARP) Candidate - ChartMill

Apr 02, 2026

Biogen to Acquire Apellis Pharmaceuticals in $5.6 Billion Deal - eHealth Magazine

Apr 02, 2026

Roth/MKM downgrades Apellis stock rating on Biogen acquisition - Investing.com

Apr 02, 2026

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) - Sahm

Apr 02, 2026

Apr 01, 2026

Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last? - qz.com

Apr 01, 2026

Biogen Acquires Apellis for $5.6B, Shares Dip | Strategic Immunology MoveNews and Statistics - indexbox.io

Apr 01, 2026

APLS: Barclays Raises Price Target for Apellis Pharmaceuticals | - GuruFocus

Apr 01, 2026

APLS: JP Morgan Downgrades Apellis Pharmaceuticals, Raises Price Target | APLS Stock News - GuruFocus

Apr 01, 2026

Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets - BioPharma Dive

Apr 01, 2026

How The Apellis Pharmaceuticals (APLS) Investment Story Is Shifting With New Deals And Analyst Revisions - Yahoo Finance

Apr 01, 2026